Safety, Tolerance, Pharmacokinetics and Activity of HE3286 in Patients With Rheumatoid Arthritis
Completed · Phase 1/Phase 2
Conditions studied: Rheumatoid Arthritis
In brief
The purpose of this pilot, exploratory study is to evaluate the safety, tolerance, pharmacokinetics and potential anti-inflammatory activity of an investigational agent, HE3286, when administered orally for 29 days to patients with rheumatoid arthritis that are taking a stable dose of methotrexate.
Key facts
- Study ID
- NCT00712114
- Run by
- Harbor Therapeutics
- People needed
- 14
- Starts
- 2008-07-01
- Expected to finish
- 2009-07-01
- Last updated by the study team
- 2011-06-14
Who can join
Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Study site — Beverly Hills, California, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.